StockStory Flags Three Concerns for Teleflex (TFX) Amid Sales Declines and Margin Pressure

Analysts at StockStory highlighted three reasons to sell Teleflex (TFX) in a report on June 5, 2026, pointing to declining sales, lagging constant currency growth, and deteriorating free cash flow margins. The medical device maker's sales fell at a 3.6% annual rate over five years, while constant currency revenue growth averaged just 3.8%—trailing the surgical equipment sector. Its free cash flow margin dropped 19.8 percentage points to breakeven over the trailing 12 months, signaling rising capital intensity. Teleflex shares trade at $132.09, or 17 times forward earnings. StockStory said that valuation reflects excessive optimism and suggests better opportunities exist elsewhere, advising investors to look at a top digital advertising platform instead.